Allostery Investments LP Buys Shares of 73,314 Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Allostery Investments LP bought a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 73,314 shares of the company's stock, valued at approximately $545,000. Avalo Therapeutics comprises approximately 0.6% of Allostery Investments LP's investment portfolio, making the stock its 25th biggest position. Allostery Investments LP owned approximately 0.71% of Avalo Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its holdings in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP acquired a new stake in Avalo Therapeutics in the 4th quarter valued at $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth about $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $168,000. Finally, Bank of Montreal Can bought a new position in shares of Avalo Therapeutics in the fourth quarter valued at approximately $446,000. Institutional investors own 87.06% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AVTX shares. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $23.00 price target on the stock. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an "overweight" rating and a $48.00 price objective on the stock. Wedbush restated an "outperform" rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Stifel Nicolaus began coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $36.00 target price for the company. Finally, HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.

Avalo Therapeutics Stock Performance

NASDAQ AVTX traded down $0.31 on Wednesday, reaching $4.47. The stock had a trading volume of 19,580 shares, compared to its average volume of 52,699. Avalo Therapeutics, Inc. has a 1-year low of $4.15 and a 1-year high of $16.00. The firm has a fifty day moving average of $6.30 and a two-hundred day moving average of $8.29.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.